Exonate is a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases which may lead to vision loss. Our lead asset, EXN407, has the potential to be the first topical treatment for retinal vascular diseases, including diabetic retinopathy and diabetic macular oedema. The asset met all endpoints and displayed encouraging signals of efficacy in diabetic patients with retinal eye disease (diabetic macular oedema) in a Phase Ib/IIa trial.